BioAtla Q4 EPS $(0.56) Beats $(0.79) Estimate
Portfolio Pulse from dijoy@benzinga.com
BioAtla (NASDAQ:BCAB) reported Q4 losses of $(0.56) per share, surpassing the analyst consensus estimate of $(0.79) by 29.11%. This represents an 11.11% improvement over the $(0.63) per share loss from the same period last year.
March 26, 2024 | 9:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioAtla reported a smaller than expected Q4 loss of $(0.56) per share, beating estimates and showing improvement over last year.
Beating the EPS estimate by a significant margin and showing year-over-year improvement is generally viewed positively by the market. This could lead to increased investor confidence in BioAtla, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100